Prothrombotic role of antiphospholipid antibodies in a patient with sickle cell disease

Annamaria Petrungaro; Eugenia Quartarone; Luciana Rigoli; Paolo Sciarrone; Annamaria Petrungaro; Eugenia Quartarone; Luciana Rigoli; Paolo Sciarrone

doi:10.3934/medsci.2022017

AIMS Medical Science

2022, Volume 9, Issue 3: 362-366. doi: 10.3934/medsci.2022017

Previous Article Next Article

Case report Topical Sections

Prothrombotic role of antiphospholipid antibodies in a patient with sickle cell disease

Unit of Transfusion Medicine, Department of Services, University Hospital “G. Martino”, Messina, Italy

Received: 03 February 2022 Revised: 15 May 2022 Accepted: 17 May 2022 Published: 02 June 2022

Sickle cell disease (SCD) is a common inherited condition in African, Caribbean, and Mediterranean countries. SCD is a hematologic disorder caused by a well-characterized point mutation in the β-globin gene, which produces an abnormal hemoglobin S that results in the sickling of red blood cells in deoxygenated conditions. Patients with SCD display a “hypercoagulation state” leading to an increased risk of severe venous and arterial thrombotic vascular events. Herein we report a case of severe thrombotic complications in a patient with SCD who showed high antiphospholipid antibodies (APA) levels during vascular occlusions.
- antiphospholipid antibodies,
- sickle cell disease,
- hypercoagulation state,
- thrombotic complications
Citation: Annamaria Petrungaro, Eugenia Quartarone, Luciana Rigoli, Paolo Sciarrone. Prothrombotic role of antiphospholipid antibodies in a patient with sickle cell disease[J]. AIMS Medical Science, 2022, 9(3): 362-366. doi: 10.3934/medsci.2022017

Related Papers:

Abstract

Sickle cell disease (SCD) is a common inherited condition in African, Caribbean, and Mediterranean countries. SCD is a hematologic disorder caused by a well-characterized point mutation in the β-globin gene, which produces an abnormal hemoglobin S that results in the sickling of red blood cells in deoxygenated conditions. Patients with SCD display a “hypercoagulation state” leading to an increased risk of severe venous and arterial thrombotic vascular events. Herein we report a case of severe thrombotic complications in a patient with SCD who showed high antiphospholipid antibodies (APA) levels during vascular occlusions.

Declarations

Ethics approval and consent to participate. This manuscript does not report on or involve the use of any animal or human data or tissue.

Conflict of interest

The authors declare no conflict of interest.

References

[1]	Piel FB, Steinberg MH, Rees DC (2017) Sickle cell disease. N Engl J Med 376: 1561-1573. https://doi.org/10.1056/NEJMra1510865
[2]	Noubiap JJ, Temgoua MN, Tankeu R, et al. (2018) Sickle cell disease, sickle trait and the risk for venous thromboembolism: a systematic review and meta-analysis. Thromb J 16: 27. https://doi.org/10.1186/s12959-018-0179-z
[3]	Conran N, De Paula EV (2020) Thromboinflammatory mechanisms in sickle cell disease—challenging the hemostatic balance. Haematologica 105: 2380-2390. https://doi.org/10.3324/haematol.2019.239343
[4]	Dowling MM, Quinn CT, Rogers ZR, et al. (2009) Stroke in sickle cell anemia: alternative etiologies. Pediatr Neurol 41: 124-126. https://doi:10.1016/j.pediatrneurol.2009.02.011
[5]	Aygun B, Padmanabhan S, Paley C, et al. (2002) Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. Transfusion 42: 37-43. https://doi.org/10.1046/j.1537-2995.2002.00007.x
[6]	Nsiri B, Ghazouani E, Gritli N, et al. (1998) Antiphospholipid antibodies: lupus anticoagulants, anticardiolipin and antiphospholipid isotypes in patients with sickle cell disease. Hematol Cell Ther 40: 107-112.
[7]	Olayemi EE, Bazuaye GN (2009) Lupus anticoagulant and leg ulcers in sickle cell anemia. Indian J Dermatol 54: 251-254. https://doi.org/10.4103/0019-5154.55635
[8]	Diatta A, Touré-Fall AO, Sarr NG, et al. (2004) Prevalence of antiphospholipid antibodies in patients with sickle cell disease. Ann Biol Clin (Paris) 62: 291-294.
[9]	Hannemann A, Rees DC, Brewin JN, et al. (2018) Oxidative stress and phosphatidylserine exposure in red cells from patients with sickle cell anaemia. Br J Haematol 182: 567-578. https://doi.org/10.1111/bjh.15441
[10]	Merashli M, Arcaro A, Graf M, et al. (2021) Antiphospholipid antibodies in sickle cell disease: A systematic review and exploratory meta-analysis. Clin Appl Thromb Hemost 27: 10760296211002914. https://doi.org/10.1177/10760296211002914
[11]	Robazzi TC, Alves C, Abreu L, et al. (2015) Coexisting systemic lupus erythematosus and sickle cell disease: case report and literature review. Rev Bras Reumatol 55: 68-74. https://doi.org/10.1016/j.rbr.2013.05.005
[12]	Christiaens C, Florkin B, Philippet P (2020) Coexistence of sickle cell disease and systemic lupus erythematosus. Rev Med Liege 75: 115-120.
[13]	De Ceulaer K, Khamashta MA, Harris EN, et al. (1992) Antiphospholipid antibodies in homozygous sickle cell disease. Ann Rheum Dis 51: 671-672. https://doi.org/10.1136/ard.51.5.671
[14]	Kucuk O, Gilman-Sachs A, Beaman K, et al. (1993) Antiphospholipid antibodies in sickle cell disease. Am J Hematol 42: 380-383. https://doi.org/10.1002/ajh.2830420409
[15]	Piccin A, O'Connor-Byrne N, Daves M, et al. (2022) Autoimmune disease and sickle cell anaemia: “Intersecting pathways and differential diagnosis”. Br J Haematol 197: 518-528. https://doi.org/10.1111/bjh.18109

Reader Comments

Your name:*

Email:*
© 2022 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)